JBIO
Jade Biosciences, Inc. trades as JBIO and has a market capitalization of $755.21 M, making it the #2665 largest US-listed company by market value. This page tracks Jade Biosciences, Inc. through 479 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| EFFECT | - | 2026-05-15 |
| EFFECT | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| 424B3 | - | 2026-05-15 |
| Employee stock plan | S-8 | 2026-05-07 |
| Securities registration | S-3 | 2026-05-07 |
| Securities registration | S-3 | 2026-05-07 |
| 424B3 | - | 2026-05-07 |
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
The largest companies sharing Jade Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Jade Biosciences, Inc. (JBIO) has a market capitalization of $755.21 M as of 2026-06-10, ranking #2665 among US-listed companies.
In its latest fiscal year Jade Biosciences, Inc. reported a net loss of $127.41M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.